Form 4: Myriad Genetics Director Sells Shares Under 10b5-1 Plan

Myriad Genetics Director Rashmi Kumar reported a sale of 15,000 shares of common stock, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Director Rashmi Kumar sold 15,000 shares of Myriad Genetics Inc. common stock.
• The sale occurred on June 8, 2026, at a weighted average price of $4.4562 per share.
• The transactions were conducted under a Rule 10b5-1 trading plan, which is designed to comply with SEC safe harbor provisions.
• Following the sale, Rashmi Kumar beneficially owns 171,889 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the insider sale, despite the execution under a Rule 10b5-1 plan, which is a standard practice.

Negatives

• A director sold a significant number of shares, which could be perceived negatively by the market, although it was executed under a pre-planned trading strategy.

Risks

• The sale of shares by a director, even under a Rule 10b5-1 plan, could be interpreted by the market as a lack of confidence in the company's near-term prospects.
• The weighted average sale price of $4.4562, with individual sales ranging from $4.37 to $4.63, might indicate a price point that the seller believed was opportune for divestment.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under Rule 10b5-1 plans, are common in the biotechnology and genetics sector. These plans allow insiders to sell shares at predetermined times or prices, mitigating concerns about insider trading while still allowing for portfolio diversification or liquidity needs. The price range of the sale may reflect current market valuations for companies in this space.

Stakeholder Impact

• Shareholders: May view the director's sale as a potential negative signal, although the Rule 10b5-1 plan mitigates concerns about opportunistic trading.
• Management: The sale by a director is a standard disclosure and does not directly impact other management members' roles.

Key Dates

Keywords

Myriad Genetics, MYGN, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Director Transaction, Beneficial Ownership